GlassScriptPhysician profile
Harpal Bhaika
NPI 1982619763
$3,639.05
in general payments reported to CMS, 2019-2025
23 companies · $833 in 2025
The $833 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $133 · 2021: $518 · 2022: $766 · 2023: $616 · 2024: $317 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,318.24 | 2019-2025 | Skyrizi, Rinvoq, Duopa |
| Gilead Sciences, INC. | $425.01 | 2019-2025 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $403.33 | 2019-2025 | Tremfya |
| Celgene Corporation | $392.79 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $175.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $151.35 | 2019-2023 | Ocaliva |
| Boston Scientific Corporation | $135.66 | 2025 | Axios |
| Takeda Pharmaceuticals U.S.A., INC. | $132.44 | 2019-2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $91.36 | 2020-2022 | |
| Daiichi Sankyo INC. | $57.24 | 2022-2023 | Injectafer |
| Shionogi INC | $56.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.20 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $38.11 | 2021-2023 | Dificid |
| Redhill Biopharma INC. | $31.70 | 2022-2023 | Talicia |
| Pfizer INC. | $29.16 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $25.69 | 2020 | |
| Phathom Pharmaceuticals, INC. | $22.47 | 2025 | Voquezna |
| Evoke Pharma, INC. | $22.16 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.01 | 2023 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $16.40 | 2022 | |
| Olympus America INC. | $14.70 | 2024 | Evis X1 Video System Center |
| Genzyme Corporation | $13.92 | 2023 | |
| Allergan, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harpal Bhaika listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.